[Treatment of venous thromboembolism].
Rocha
E
E
Servicio de Hematología y Hemoterapia, Universidad de Navarra, Pamplona. erocha@unav.es
Panizo
C
C
Lecumberri
R
R
D000284:Administration, Oral; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D017131:Thrombectomy; D013923:Thromboembolism / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D015912:Thrombolytic Therapy; D013997:Time Factors; D016306:Vena Cava Filters; D020246:Venous Thrombosis / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use
D000925:Anticoagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D014859:Warfarin; D006493:Heparin